Hongmian Zhao Selected Research

Cytarabine (Cytosar-U)

1/2020	HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
4/2019	MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hongmian Zhao Research Topics

Disease

11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 01/2018
5	Neoplasms (Cancer) 01/2020 - 01/2018
2	Leukemia 01/2020 - 01/2019
2	Multiple Myeloma 07/2018 - 01/2018
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Pathologic Processes 03/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2019
1	Colonic Neoplasms (Colon Cancer) 01/2018

Drug/Important Bio-Agent (IBA)

4	Long Noncoding RNAIBA 04/2019 - 01/2018
3	Biological ProductsIBA 03/2019 - 01/2018
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 04/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2019 - 01/2019
1	deoxyshikoninIBA 01/2020
1	adenylate kinase 1IBA 01/2020
1	Small Interfering RNA (siRNA)IBA 01/2020
1	CateninsIBA 01/2020
1	Taurine FDA Link 04/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	ArtesunateIBA 01/2019

Therapy/Procedure

3	Hematopoietic Stem Cell Transplantation 01/2020 - 01/2018
2	Drug Therapy (Chemotherapy) 01/2020 - 01/2019
1	Therapeutics 07/2018